- Home
- CPRI vs IBRX Comparison
CPRI vs IBRX Comparison
Compare CPRI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRI
- IBRX
- Stock Information
- Founded
- CPRI 1981
- IBRX 2014
- Country
- CPRI United Kingdom
- IBRX United States
- Employees
- CPRI N/A
- IBRX N/A
- Industry
- CPRI Apparel
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPRI Consumer Discretionary
- IBRX Health Care
- Exchange
- CPRI Nasdaq
- IBRX Nasdaq
- Market Cap
- CPRI 2.2B
- IBRX 2.3B
- IPO Year
- CPRI 2011
- IBRX N/A
- Fundamental
- Price
- CPRI $19.15
- IBRX $2.54
- Analyst Decision
- CPRI Buy
- IBRX Strong Buy
- Analyst Count
- CPRI 11
- IBRX 5
- Target Price
- CPRI $22.18
- IBRX $11.40
- AVG Volume (30 Days)
- CPRI 2.4M
- IBRX 7.4M
- Earning Date
- CPRI 08-06-2025
- IBRX 08-11-2025
- Dividend Yield
- CPRI N/A
- IBRX N/A
- EPS Growth
- CPRI N/A
- IBRX N/A
- EPS
- CPRI N/A
- IBRX N/A
- Revenue
- CPRI $4,442,000,000.00
- IBRX $31,222,000.00
- Revenue This Year
- CPRI N/A
- IBRX $567.98
- Revenue Next Year
- CPRI $4.53
- IBRX $160.56
- P/E Ratio
- CPRI N/A
- IBRX N/A
- Revenue Growth
- CPRI N/A
- IBRX 10238.41
- 52 Week Low
- CPRI $11.86
- IBRX $1.83
- 52 Week High
- CPRI $43.34
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- CPRI 53.99
- IBRX 40.63
- Support Level
- CPRI $18.86
- IBRX $2.64
- Resistance Level
- CPRI $20.00
- IBRX $3.11
- Average True Range (ATR)
- CPRI 0.71
- IBRX 0.18
- MACD
- CPRI -0.03
- IBRX -0.02
- Stochastic Oscillator
- CPRI 46.46
- IBRX 1.72
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.